Antengene enters into a global clinical collaboration with MSD to evaluate ATG-022 (CLDN18.2 ADC) in combination with KEYTRUDA (Pembrolizumab)

CAR-T Digest - August 2020

Weekly Digest - May 2025

20 May 2025: Antengene enters into a global clinical collaboration with MSD to evaluate ATG-022 (CLDN18.2 ADC) in combination with KEYTRUDA (Pembrolizumab)

Antengene has entered a global clinical collaboration with MSD to evaluate ATG-022 (a CLDN18.2-targeting ADC) in combination with KEYTRUDA (Pembrolizumab) for treating advanced solid tumors
In the Phase I/II CLINCH study presented at ASCO GI 2025, ATG-022 achieved an ORR of 9% and DCR of 95.2% in patients with moderate to high CLDN18.2 expression
The study also showed notable activity in low CLDN18.2 expressors (ORR 30%, DCR 50.0%), suggesting broad potential efficacy across expression levels
ATG-022 demonstrated good tolerability, with no ophthalmologic, neurologic toxicities, or interstitial lung disease observed
Due to its efficacy across high, low, and ultra-low CLDN18.2 expression levels, ATG-022 could address a wider gastric cancer patient population compared to existing therapies